Ulcavis pills 120mg №56

Trade name: Ulcavis

Pharmaceutical form

Tablets, film coated. Round slightly biconvex tablets, film-coated white or almost white color, with a facet.
View of the fracture: a rough mass of white color with a shell of white or almost white color.

Indications for use

• Peptic ulcer of the stomach and duodenum in the acute phase, including associated with Helicobacter pylori.
• Chronic gastritis and gastroduodenitis in the acute phase, including associated with Helicobacter pylori.
• Irritable bowel syndrome, predominantly with diarrhea symptoms.
• Functional dyspepsia, not associated with organic diseases of the gastrointestinal tract.

Dosage and administration

For adults and children over 12 years old, Ulcavis is prescribed 1 pill 4 times a day 30 minutes before meals and 2 nights or 2 pills 2 times a day 30 minutes before meals.
For children from 8 to 12 years old, Ulcavis is prescribed 1 pill 2 times a day 30 minutes before meals.
Children from 4 to 8 years old are prescribed at a dose of 8 mg / kg / day, depending on the body weight of the child, 1-2 pills per day are administered (respectively, 1-2 doses per day, respectively). In this case, the daily dose should be closest to the estimated dose (8 mg / kg / day).
Tablets are taken 30 minutes before meals with a small amount of water.
The duration of treatment is 4-8 weeks. For the next 8 weeks, do not use bismuth-containing drugs.
For the eradication of Helicobacter pylori, it is advisable to use the drug Ulcavis in combination with other antibacterial agents with anti-helicobacter activity (as recommended by the doctor).

Contraindications

Severe renal failure (creatinine clearance less than 30 ml / min), pregnancy, breastfeeding period, idiosyncrasy of the drug, children up to 4 years.

Special notes

Ulcavis should not be used for more than 8 weeks. It is also not recommended during treatment to exceed the prescribed daily doses for adults and children. During the period of treatment with Ulcavis, other drugs containing bismuth should not be used.At the end of the course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 μg / l, and intoxication is observed only when the concentration in the blood plasma is above 100 μg / l.
When using the drug Ulcavis, it is possible to stain feces in a dark color due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.

Interaction with other drugs

Within half an hour before and after taking the drug Ulcavis, it is not recommended to use inside other medicines, as well as food and liquid intake, in particular, antacids, milk, fruit and fruit juices. This is due to the fact that they, while being swallowed, can affect the efficacy of Ulcavis.
The simultaneous use of the drug Ulcavis with Tetracycline reduces the absorption of the latter.

Use during pregnancy and during breastfeeding

The use of the drug Ulcavis during pregnancy and during breastfeeding is contraindicated.
Impact on the ability to perform potentially hazardous activities that require special attention and quick reactions (for example, driving, working with moving machinery)
Data on the effect of the drug Ulcavis on the ability to drive vehicles and mechanisms are missing.

Side effect

On the part of the digestive system: possible nausea, vomiting, more frequent stools, constipation. These phenomena are not dangerous to health and are temporary.
Allergic reactions: skin rash, pruritus.
With prolonged use in high doses may develop encephalopathy associated with the accumulation of bismuth in the central nervous system.

Overdosage

An overdose of the drug Ulcavis, caused by prolonged doses higher than recommended, can lead to impaired renal function. These symptoms are completely reversible with discontinuation of the drug Ulcavis.
If signs of poisoning appear, it is necessary to: flush the stomach, take activated charcoal and saline laxatives. Further treatment should be symptomatic. In the event of impaired renal function, which is accompanied by a high concentration of bismuth in the blood plasma, chelation agents (penicillamine, sodium dimercaptopropanesulfonate) can be administered. In the case of pronounced renal impairment, hemodialysis is indicated.

Pharmacotherapeutic group: antiseptic intestinal and astringent

Pharmacological properties

Pharmacodynamics
Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate precipitate, chelate compounds are formed with a protein substrate in the form of a protective film on the surface of ulcers and erosions. Increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, stimulates the activity of cytoprotective mechanisms, increases the resistance of the mucous membrane of the gastrointestinal tract to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the area of ​​the defect. Reduces the activity of pepsin.

Pharmacokinetics

Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. Excreted mainly through the intestines with feces. A small amount of bismuth entering the blood plasma is excreted by the kidneys.

Shelf life

Do not use the drug after the expiration date.

Storage conditions

At a temperature not higher than 25 ° С, in the original package.
Keep out of the reach of children.

Vacation conditions

Let go without a prescription.